Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiologys Annual Scientific Session & Expo (ACC.25)
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and…
AK BETS – EARLY PAYOUTS – LIVERPOOL, LEEDS, BIRMINGHAM & CELTIC
Thursday 27 February, 2025 Bookmaker AK BETS has today paid out on…
Global Supply Chains Forced to Change Rapidly As World Trade Enters New Era According to Economist Impact and DP World
Non-aligned nations fast emerging as vital intermediaries in mitigating trade risks, filling…
